Characterization of epitope-specific anti-respiratory syncytial virus (anti-RSV) antibody responses after natural infection and after vaccination with formalin-inactivated RSV

Journal of Virology

Volumn 90, Issue 13, 2016, Pages 5965-5977

  Widjaja, Ivy ^a,b   Wicht, Oliver ^c   Luytjes, Willem ^c   Leenhouts, Kees ^b   Rottier, Peter J M ^a   van Kuppeveld, Frank J M ^a   Haijema, Bert Jan ^b   de Haan, Cornelis A M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Mucosis BV Meditech Center   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; ATTACHMENT PROTEIN G; FORMALDEHYDE; INACTIVATED VACCINE; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS NEUTRALIZATION; ADVERSE EFFECTS; ANIMAL; BLOOD; CHEMISTRY; GENETICS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INNATE IMMUNITY; SIGMODONTINAE; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EPITOPES; FORMALDEHYDE; HUMANS; IMMUNITY, INNATE; IMMUNODOMINANT EPITOPES; RATS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SIGMODONTINAE; VACCINATION; VACCINES, INACTIVATED; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS; VIRAL PROTEINS;

EID: 84975282721     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00235-16     Document Type: Article

References (46)

1. Hall CB, Simoes EA, Anderson LJ. 2013. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol 372: 39-57. http://dx.doi.org/10.1007/978-3-642-38919-1_2.
2. Krishnamoorthy N, Khare A, Oriss TB, Raundhal M, Morse C, Yarlagadda M, Wenzel SE, Moore ML, Peebles RS, Jr, Ray A, Ray P. 2012. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat Med 18:1525-1530. http://dx.doi.org/10.1038/nm.2896.
3. Falsey AR, Walsh EE. 2005. Respiratory syncytial virus infection in elderly adults. Drugs Aging 22:577-587. http://dx.doi.org/10.2165/00002512-200522070-00004.
4. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162: 80-99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
5. Murphy BR, Walsh EE. 1988. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26:1595-1597.
6. Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM. 1986. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 57:721-728.
7. Christiaansen AF, Knudson CJ, Weiss KA, Varga SM. 2014. The CD4 T cell response to respiratory syncytial virus infection. Immunol Res 59: 109-117. http://dx.doi.org/10.1007/s12026-014-8540-1.
8. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15:34-41. http://dx.doi.org/10.1038/nm.1894.
9. Collins PL, Graham BS. 2008. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82:2040-2055. http://dx.doi.org/10.1128/JVI.01625-07.
10. Melero JA, Mas V. 1 March 2015. The Pneumovirinae fusion (F) protein: a common target for vaccines and antivirals. Virus Res http://dx.doi.org/10.1016/j.virusres.2015.02.024.
11. McLellan JS. 2015. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol 11:70-75. http://dx.doi.org/10.1016/j.coviro.2015.03.002.
12. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. 2013. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A 110:11133-11138. http://dx.doi.org/10.1073/pnas.1309070110.
13. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788-7796. http://dx.doi.org/10.1128/JVI.00555-11.
14. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:1113-1117. http://dx.doi.org/10.1126/science.1234914.
15. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 108: 9619-9624. http://dx.doi.org/10.1073/pnas.1106536108.
16. Widjaja I, Rigter A, Jacobino S, van Kuppeveld FJ, Leenhouts K, Palomo C, Melero JA, Leusen JH, Haijema BJ, Rottier PJ, de Haan CA. 2015. Recombinant soluble respiratory syncytial virus F protein that lacks heptad repeat B, contains a GCN4 trimerization motif and is not cleaved displays prefusion-like characteristics. PLoS One 10:e0130829. http://dx.doi.org/10.1371/journal.pone.0130829.
17. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592-598. http://dx.doi.org/10.1126/science.1243283.
18. Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJ, Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, Langedijk JP. 2015. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 6:8143. http://dx.doi.org/10.1038/ncomms9143.
19. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, Terron MC, Melero JA, Palomo C. 2012. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A 109:3089-3094. http://dx.doi.org/10.1073/pnas.1115941109.
20. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, Yassine HM, Moin SM, Killikelly AM, Chuang GY, Druz A, Georgiev IS, Rundlet EJ, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Nason MC, Capella C, Peeples ME, Ledgerwood JE, McLellan JS, Kwong PD, Graham BS. 2015. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7:309ra162. http://dx.doi.org/10.1126/scitranslmed.aac4241.
21. Rigter A, Widjaja I, Versantvoort H, Coenjaerts FE, van Roosmalen M, Leenhouts K, Rottier PJ, Haijema BJ, de Haan CA. 2013. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One 8:e71072. http://dx.doi.org/10.1371/journal.pone.0071072.
22. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176:1215-1224. http://dx.doi.org/10.1086/514115.
23. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, van Bleek GM, Widjojoatmodjo MN, Bogers WM, Mei H, Radbruch A, Scheeren FA, Spits H, Beaumont T. 2010. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 16:123-128. http://dx.doi.org/10.1038/nm.2071.
24. Zeng Q, Langereis MA, van Vliet AL, Huizinga EG, de Groot RJ. 2008. Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci U S A 105:9065-9069. http://dx.doi.org/10.1073/pnas.0800502105.
25. de Vries RP, de Vries E, Bosch BJ, de Groot RJ, Rottier PJ, de Haan CA. 2010. The influenza A virus hemagglutinin glycosylation state affects receptor-binding specificity. Virology 403:17-25. http://dx.doi.org/10.1016/j.virol.2010.03.047.
26. Harbury PB, Zhang T, Kim PS, Alber T. 1993. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262:1401-1407. http://dx.doi.org/10.1126/science.8248779.
27. Bosch BJ, Bodewes R, de Vries RP, Kreijtz JH, Bartelink W, van Amerongen G, Rimmelzwaan GF, de Haan CA, Osterhaus AD, Rottier PJ. 2010. Recombinant soluble, multimericHAandNAexhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J Virol 84:10366-10374. http://dx.doi.org/10.1128/JVI.01035-10.
28. Widjojoatmodjo MN, Boes J, van Bers M, van Remmerden Y, Roholl PJ, Luytjes W. 2010. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol J 7:114. http://dx.doi.org/10.1186/1743-422X-7-114.
29. Prince GA, Curtis SJ, Yim KC, Porter DD. 2001. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82:2881-2888. http://dx.doi.org/10.1099/0022-1317-82-12-2881.
30. van Remmerden Y, Xu F, van Eldik M, Heldens JG, Huisman W, Widjojoatmodjo MN. 2012. An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting. Virol J 9:253. http://dx.doi.org/10.1186/1743-422X-9-253.
31. Rao Q, Hsieh YH. 2008. Competitive enzyme-linked immunosorbent assay for quantitative detection of bovine blood in heat-processed meat and feed. J Food Prot 71:1000-1006.
32. Acosta PL, Caballero MT, Polack FP. 16 December 2015. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol http://dx.doi.org/10.1128/CVI.00609-15.
33. Falsey AR, Singh HK, Walsh EE. 2006. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 78: 1493-1497. http://dx.doi.org/10.1002/jmv.20724.
34. Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, de Haan CA, Wrammert J, Openshaw PJ, Chiu C, and Mechanisms of Severe Acute Influenza Consortium Investigators. 2015. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med 191:1040-1049. http://dx.doi.org/10.1164/rccm.201412-2256OC.
35. Connor AL, Bevitt DJ, Toms GL. 2001. Comparison of human respiratory syncytial virus A2 and 8/60 fusion glycoprotein gene sequences and mapping of sub-group specific antibody epitopes. J Med Virol 63:168-177.
36. Yunus AS, Jackson TP, Crisafi K, Burimski I, Kilgore NR, Zoumplis D, Allaway GP, Wild CT, Salzwedel K. 2010. Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation. Virology 396:226-237. http://dx.doi.org/10.1016/j.virol.2009.10.040.
37. Chaiwatpongsakorn S, Epand RF, Collins PL, Epand RM, Peeples ME. 2011. Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer. J Virol 85:3968-3977. http://dx.doi.org/10.1128/JVI.01813-10.
38. Tsui P, Tornetta MA, Ames RS, Bankosky BC, Griego S, Silverman C, Porter T, Moore G, Sweet RW. 1996. Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning. J Immunol 157:772-780.
39. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL. 1986. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A 83:7462-7466. http://dx.doi.org/10.1073/pnas.83.19.7462.
40. Martínez I, Melero JA. 1998. Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J Gen Virol 79(Pt 9):2215-2220. http://dx.doi.org/10.1099/0022-1317-79-9-2215.
41. Johnson SM, McNally BA, Ioannidis I, Flano E, Teng MN, Oomens AG, Walsh EE, Peeples ME. 2015. Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog 11:e1005318. http://dx.doi.org/10.1371/journal.ppat.1005318.
42. Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, Zhu Q, Kabeche SC, Kumar A, Palomo C, Beaumont T, Baxa U, Ulbrandt ND, Melero JA, Graham BS, McLellan JS. 2015. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog 11:e1005035. http://dx.doi.org/10.1371/journal.ppat.1005035.
43. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, Guarino B, Silacci C, Marcandalli J, Marsland BJ, Piralla A, Percivalle E, Sallusto F, Baldanti F, Lanzavecchia A. 2013. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501:439-443. http://dx.doi.org/10.1038/nature12442.
44. Graham BS. 1995. Pathogenesis of respiratory syncytial virus vaccineaugmented pathology. Am J Respir Crit Care Med 152:S63-S66. http://dx.doi.org/10.1164/ajrccm/152.4_Pt_2.S63.
45. Krilov LR, Anderson LJ, Marcoux L, Bonagura VR, Wedgwood JF. 1989. Antibody-mediated enhancement of respiratory syncytial virus infection in two monocyte/macrophage cell lines. J Infect Dis 160:777-782. http://dx.doi.org/10.1093/infdis/160.5.777.
46. Delvecchio A, Tsui P, Branigan P, Conrad L, Day N, Liu C, Sweet R, Wu SJ, Melero J, Luo J. July 2006. Anti-respiratory syncytial virus antibodies, antigens and uses thereof. US patent 20060159695 A1.